Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine
- 30 April 2009
- journal article
- Published by Elsevier BV in Journal of Clinical Virology
- Vol. 44 (4), 287-291
- https://doi.org/10.1016/j.jcv.2009.01.009
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Regulation of airway eosinophil and neutrophil infiltration by α-galactosylceramide in a mouse model for respiratory syncytial virus (RSV) vaccine-augmented diseaseVaccine, 2007
- Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussisClinical and Experimental Immunology, 2006
- Modulation of Protective Immunity, Eosinophilia, and Cytokine Responses by Selective Mutagenesis of a Recombinant G Protein Vaccine against Respiratory Syncytial VirusJournal of Virology, 2005
- The immunomodulating properties of human respiratory syncytial virus and immunostimulating complexes containingQuillajasaponin components QH-A, QH-C and ISCOPREPTM703FEMS Immunology & Medical Microbiology, 2005
- Protollin™: a novel adjuvant for intranasal vaccinesVaccine, 2004
- Recombinant Sendai Virus Expressing the G Glycoprotein of Respiratory Syncytial Virus (RSV) Elicits Immune Protection against RSVJournal of Virology, 2004
- Adjuvants recognized by toll-like receptors inhibit the induction of polarized type 2 T cell responses by natural attachment (G) protein of respiratory syncytial virusVaccine, 2003
- Plasmid DNA encoding the respiratory syncytial virus G protein protects against RSV-induced airway hyperresponsivenessVaccine, 2002
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Liposome encapsulation of a soluble recombinant fragment of the respiratory syncytial virus (RSV) G protein enhances immune protection and reduces lung eosinophilia associated with virus challengeVaccine, 2000